EID2 (EP300 interacting inhibitor of differentiation 2) functions as a transcriptional co-repressor that negatively regulates multiple signaling pathways. The protein directly interacts with the histone acetyltransferase EP300/CBP and inhibits its activity, thereby repressing MYOD-dependent transcription and muscle differentiation 1. EID2 also acts as a repressor of TGFβ/SMAD transcriptional responses by selectively blocking the formation of TGFβ-induced SMAD3-SMAD4 complexes. Structurally, EID2 contains a conserved Nse3/MAGE-binding domain (NMBD) that enables protein-protein interactions with MAGE family proteins, suggesting evolutionary conservation of this binding interface 2. In disease contexts, EID2 expression appears dysregulated in various conditions. The gene shows increased expression in damaged cartilage compared to healthy tissue, potentially contributing to cartilage pathology 3. Additionally, EID2 is among genes that exhibit altered expression patterns in monkeypox-infected cells during viral replication 4 and is detectable in bile extracellular vesicles from cancer patients 5. These findings suggest EID2 may serve as a biomarker for certain pathological conditions, though its precise role in disease pathogenesis requires further investigation.